Negative Pressure Wound Therapy in the Outpatient Setting
Durable Medical Equipment
Original Policy Date
Last Review Status/Date
|Return to Medical Policy Index|
The management and treatment of chronic wounds, including decubitus ulcers, remain a treatment challenge. Most chronic wounds will heal only if the underlying cause, ie, venous stasis, pressure, infection, etc., is addressed. In addition, cleaning the wound to remove nonviable tissue, microorganisms, and foreign bodies is essential to create the optimal conditions for either re-epithelialization (ie, healing by secondary intention) or preparation for wound closure with skin grafts or flaps (ie, healing by primary intention). Therefore, debridement, irrigation, whirlpool treatments, and wet-to-dry dressings are common components of chronic wound care.
Negative pressure wound therapy (NPWT) consists of the use of a negative pressure therapy or suction device to aspirate and remove fluids, debris, and infectious materials from the wound bed to promote the formation of granulation tissue. The devices may be used as an adjunct to surgical therapy or as an alternative to surgery in a debilitated patient. Although the exact mechanism has not been elucidated, it is hypothesized that negative pressure contributes to wound healing by removing excess interstitial fluid, increasing the vascularity of the wound, reducing edema, and/or creating beneficial mechanical forces that lead to cell growth and expansion.
A nonpowered (mechanical) NPWT system has also been developed; 1 device is the Smart Negative Pressure (SNaP) Wound Care System. This device is portable and lightweight (3 oz) and can be worn underneath clothing. This system consists of a cartridge, dressing, and strap; the cartridge acts as the negative pressure source. The system is reported to generate negative pressure levels similar to other NPWT systems. This system is fully disposable.
The focus of this document is on use of NPWT in the outpatient setting.
Negative pressure therapy or suction devices cleared by the U.S. Food and Drug Administration (FDA) for the purpose of treating chronic wounds include, but are not limited to: V.A.C.® (Negative pressure therapy Assisted Closure®) Therapy™ (Kinetic Concepts Inc); Versatile 1™ Wound Negative pressure therapy System (Blue Sky Medical), RENASYS™ EZ and RENASYS GO systems (The latter is a portable system) (Smith&Nephew) and the PICO™ Single-Use Negative Pressure Wound Therapy System (Smith&Nephew).
Portable systems include the RENASYS™ GO (Smith&Nephew), XLR8 PLUS (Genadyne Biotechnologies), Extricare® 2400 NPWT System (Devon Medical, Inc.), and the PICO™ Single-Use Negative Pressure Wound Therapy System (Smith&Nephew).
A nonpowered NPWT device, the SNaP® Wound Care System from Spiracur, is a Class II device requiring notification to market but not having FDA premarket approval. It received 510(k) marketing clearance from FDA in 2009 (K081406) and is designed to remove small amounts of exudate from chronic, traumatic, dehisced, acute, subacute wounds and diabetic and pressure ulcers.
No NPWT device has been cleared for use in infants and children.
In November 2009, FDA issued an alert concerning complications and deaths that had been associated with NPWT systems. An updated alert was issued in February 2011. (Available online at: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm244211.htm.)
Initiation of a Powered Negative Pressure Wound Therapy (NPWT)
An initial therapeutic trial of not less than 2 weeks using a powered negative pressure wound therapy (NPWT) system, as part of a comprehensive wound care program that includes controlling factors such diabetes, nutrition, relief of pressure, etc., may be considered medically necessary in the following indications:
- Chronic (>90 days) stage III or IV pressure ulcers that have failed to heal despite optimal wound care when there is high-volume drainage that interferes with healing and/or when standard dressings cannot be maintained due to anatomic factors, or
- Traumatic or surgical wounds where there has been a failure of immediate or delayed primary closure AND there is exposed bone, cartilage, tendon, or foreign material within the wound
- Wounds in patients with underlying clinical conditions which are known to negatively impact wound healing, which are nonhealing (at least 30 days), despite optimal wound care. (Examples of underlying conditions include, but are not limited to diabetes, malnutrition, small vessel disease, and morbid obesity. Malnutrition, while a risk factor, must be addressed simultaneously with the negative pressure wound therapy.)
Continuation of Powered NPWT
Continuation of the powered NPWT system, as part of a comprehensive wound care program, may be considered medically necessary following an initial 2-week therapeutic trial if the treatment trial has resulted in documented objective improvements in the wound, and if there is ongoing objective improvement during subsequent treatment. Objective improvements in the wound should include the development and presence of healthy granulation tissue, progressive wound contracture and decreasing depth, and/or the commencement of epithelial spread from the wound margins.
Continuation of the powered NPWT system is considered not medically necessary when any of the following occurs:
- The therapeutic trial or subsequent treatment period has not resulted in documented objective improvement in the wound, OR
- The wound has developed evidence of wound complications contraindicating continued NPWT, OR
- The wound has healed to an extent that either grafting can be performed or the wound can be anticipated to heal completely with other wound care treatments.
Therapeutic trials of powered NPWT systems for the treatment of other acute or chronic wounds except as noted above are considered not medically necessary.
Use of nonpowered NPWT systems for the treatment of acute or chronic wounds is considered investigational.
Contraindications to the use of NPWT systems include the following conditions as noted by a November 2009 FDA alert: necrotic tissue with eschar, untreated osteomyelitis, nonenteric and unexplored fistulas, malignancy in the wound, exposed nerve, exposed anastomotic site, and exposed organ.
In a 2011 update, FDA noted additional deaths and injury reports with NPWT since 2009. Although rare, these complications can occur wherever NPWT systems are used, including hospitals, long-term care facilities, and at home. Bleeding was the cause of the most serious adverse events, including deaths. The majority of reports of wound infection were related to the retention of dressing pieces in the wounds. FDA recommendations for health care providers include the following: select patients for NPWT carefully knowing that NPWT systems are contraindicated for certain wound types, and patient risk factors must be thoroughly considered before use; assure that the patient is monitored frequently in an appropriate care setting by a trained practitioner; be aware of complications associated with dressing changes such as infection and bleeding; be vigilant for potentially life-threatening complications, such as bleeding, and be prepared to take prompt action if they occur. FDA reported that the safety and effectiveness of NPWT systems in newborns, infants and children has not been established at this time and currently, there are no NPWT systems cleared for use in these populations.
Continuation of healing during use of the NPWT system should be monitored on a frequency of not less than every 14 days.
Complete healing of a wound would normally be anticipated if all bone, cartilage, tendons, and foreign material were completely covered, healthy granulation were present to within 5 mm of the surface, and the wound edges were reduced to 2 cm in width or diameter.
Powered negative pressure therapy systems should be used as part of a comprehensive wound care program that includes attention to other factors that impact wound healing such as diabetes control, nutritional status, relief of pressure, etc.
The focus of these policy statements and guidelines is for use of NPWT in the outpatient setting.
In 2004, HCPCS codes were introduced that specifically describe negative pressure therapy-assisted closure as follows:
A6550: Wound care set for negative pressure wound therapy electrical pump, includes all supplies and accessories
E2402: Negative pressure wound therapy electrical pump, stationary or portable
There are 2 CPT codes for application of negative pressure wound therapy utilizing durable medical equipment:
97605: Negative pressure wound therapy (eg, negative pressure therapy-assisted drainage collection), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters
97606: total wound(s) surface area greater than 50 square centimeters
Effective in 2015, there are also CPT codes for application of negative pressure wound therapy utilizing disposable, non-durable equipment:
97607: Negative pressure wound therapy (eg, vacuum assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management collection system, topical application(s), wound assessment, and instructions for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters
97608: total wound(s) surface area greater than 50 square centimeters
In July 2011, HCPCS codes were developed specific to a NPWT system (such as the Kalypto® system) in which the exudate is collected in the dressing rather than in a canister:
K0743: Suction pump, home model, portable, for use on wounds
K0744-K0746: Code range for absorptive wound dressings to be used with home suction pump coded with K0743
Effective in 2014, the HCPCS code for a disposable NPWT system was revised to make it applicable to all types of disposable wound suction devices (such as the SNaP® or PICO™ systems):
A9272: Wound suction, disposable, includes dressing and all accessories and components, any type, each.
BlueCard/National Account Issues
State or federal mandates (e.g., FEP) may dictate that all FDA-approved or cleared devices may not be considered investigational and thus these devices may be assessed only on the basis of their medical necessity.
This policy was initially developed from a 2000 TEC Assessment(1) that evaluated negative pressure therapy of pressure ulcers, venous ulcers, and diabetic ulcers. The TEC Assessment concluded that the evidence was insufficient to permit conclusions regarding the effect of the technology on health outcomes and that the efficacy of negative pressure therapy compared to standard wound management should be determined by high-quality clinical trials that contain the following features:
- enrollment of a patient population with ulcers refractory to standard treatment after an appropriate period of optimal wound management;
- randomized assignment to treatment group;
- treatment in the control arm that includes all of the main components of optimal wound care, eg, debridement, irrigation, whirlpool treatments, and wet-to-dry dressings;
- outcome measure(s) that represent clinically important end points, such as the percent of patients with complete healing or the percent of patients who require skin grafting.
Literature updates for this policy have focused on comparative trials with the features described in the 2000 TEC Assessment, eg, enrollment of patients with ulcers refractory to standard treatment, randomization, optimal standard wound care treatment in the control arm, and clinically important end points. The most recent literature review using the MEDLINE database was performed through December 11, 2014.
Negative pressure wound therapy (NPWT) devices can be classified as either powered, ie, requiring an external power source, or nonpowered, ie, mechanical. Most evidence is for powered devices and the main discussion of evidence refers to powered devices. Evidence on nonpowered devices is discussed separately following the review of evidence on powered devices.
Mixed Wound Types
In 2004, the Blue Cross and Blue Shield Technology Evaluation Center (TEC) prepared a systematic review for the Agency for Healthcare Research and Quality (AHRQ) that concluded that available published trials “did not find a significant advantage for the intervention on the primary end point, complete healing, and did not consistently find significant differences on secondary end points and may have been insufficiently powered to detect differences.”(2) A 2008 Cochrane review concluded that “trials comparing NPWT with alternative treatments for chronic wounds have methodologic flaws and data do demonstrate a beneficial effect of NPWT on wound healing; however, more, better quality research is needed.”(3) In 2014, authors of a systematic review from the Johns Hopkins University Evidence-based Practice Center for AHRQ and the Centers for Medicare and Medicaid Services (CMS) reported that due to insufficient evidence, they were unable to draw conclusions about the efficacy or safety of NPWT in the home setting.(4)
A 2009 AHRQ technology assessment that was looking primarily for “therapeutic distinctions” between the various NPWT devices on the market was performed by ECRI Institute for CMS.(5) The Medicare Improvements for Patient and Providers Act of 2008 called for an evaluation of the HCPCS coding decisions for these devices, so this assessment was performed to inform that evaluation. The AHRQ assessment found that there were no studies showing a therapeutic distinction between these devices.
Randomized Controlled Trials
Examples of individual randomized controlled trials (RCTs) include a 2004 study by Moues et al(7) on the time to readiness for surgical closure among patients with full-thickness wounds of various etiologies. Log-rank test analysis of Kaplan-Meier method time to readiness did not show any statistically significant differences between groups. The median time to readiness for surgical closure was 6 days for negative pressure therapy patients and 7 days for conventionally treated patients (p=0.19).
Braakenburg et al (2006) compared NPWT using the V.A.C.® system (n=32) with conventional moist wound therapy (n=33) in patients with different types of wounds (operation wounds, diabetic ulcers, pressure sores) that ranged in duration from less than 48-hours-old to longer than 6 weeks.(8) Twenty-six (81%) NPWT patients and 19 (58%) conventional therapy patients reached an end point of wound healing
(p<0.05). The median healing time was 4 days shorter in the NPWT group (16 days) compared with controls (20 days), a nonsignificant difference. Substantial, unaccounted loss to follow-up (NPWT, 19%; controls, 36%) and ill-defined wound characteristics confound the results.
A publication from 2008 describes an RCT of NPWT carried out in India using a locally constructed device.(9) In this study, 48 patients with diabetic foot ulcers, pressure ulcers, cellulitis/fasciitis, and “other” were randomized to NPWT or moist dressings. One patient in the NPWT group and 12 in the conventionally treated group were lost to follow-up. No statistically significant differences in time to closure were observed between groups, except in a subset analysis of pressure ulcers (mean [SD], 10 [7.11] days for the treatment group vs 27 [10.6] days in controls; p=0.05). The high drop-out rate prevents drawing clear conclusions from this study.
Representative literature includes a small trial that randomized 24 patients with pressure ulcers of the pelvic region to negative pressure therapy or standard wound care.(10) All patients with pelvic pressure sores were eligible for enrollment and were not required to be refractory to standard treatment. There were no significant group differences for the main outcome measure, time to 50% reduction of wound volume (mean [SD], 27  days in the negative pressure therapy group and 28  days in the control group). Limitations include the small number of patients in the study, the possibility that the control group may not have received optimal wound management, and a main outcome measure of 50% reduction in wound size, which is not necessarily a clinically important outcome when compared with other potential outcomes, such as complete wound healing.
Diabetic Lower-Extremity Ulcers
A 2013 Cochrane review of NPWT for treating foot wounds in patients with diabetes mellitus included 5 randomized trials with a total of 605 participants.(11) Two of the 5 trials had a total of 502 participants; the remaining 3 trials were small, with limited reporting, and with an unclear risk of bias. One of the larger studies (described next) was conducted in patients with diabetic foot ulcers, and the second was in
patients with postamputation wounds. Both studies showed a benefit of NPWT but were considered to be at risk of performance bias due to lack of blinding.
The largest study of NPWT for diabetic foot ulcers was a 2008 multicenter, randomized controlled comparison of NPWT versus moist wound therapy by Blume et al.(12) Included were 342 patients with Wagner’s stage 2 or 3 foot ulcers at least 2 cm2 ; the chronicity of the ulcers was not described. Based on intention-to-treat analysis, a greater proportion of NPWT-treated foot ulcers achieved the primary end point of complete ulcer closure (43.2% vs 28.9%) within the 112-day active treatment phase. For the 240 patients (72%) who completed the active treatment phase, 60.8% of NPWT-treated ulcers achieved ulcer closure compared with 40.0% of ulcers treated with moist wound therapy. NPWT patients experienced significantly fewer secondary amputations (4.1% vs 10.2%). Although this study is limited by 28% loss to follow-up, and chronicity of the ulcers was not described, it is of higher quality than most of the literature in this area.
Lower-Extremity Ulcers Due to Venous Insufficiency
Vuerstaek et al (2006) compared the efficacy of NPWT using the V.A.C.® system (n=30) with conventional moist wound care (n=30) in patients hospitalized with chronic venous and/or arterial leg ulcers of greater than 6 months’ duration.(13) Full-thickness punch skin grafts from the thigh were applied, followed by 4 days of NPWT or conventional care to assure complete graft adherence. Each group then
received standard care with nonadhesive dressings and compression therapy until complete healing (primary outcome) occurred. The median time to complete healing was 29 days with NPWT and 45 days in controls (p<0.001). Ninety percent of ulcers treated with NPWT healed within 43 days, compared with 48% in the control group. These results suggest that NPWT significantly hastened wound healing, but the use of skin autografts makes it difficult to discern the contribution of NPWT to the primary outcome.
A 2012 Cochrane review identified 1 RCT of NPWT that met inclusion criteria.(14) The trial had poor reporting with an absence of data and was considered to be at high risk of bias. No conclusions could be drawn at that time regarding the use of NPWT for this indication.
In 2012, Bloemen et al reported a multicenter 4-armed randomized trial with 86 patients that compared a split-skin graft with or without a dermal substitute (Matriderm), with or without NPWT.(15) Outcome measures included graft take at 4 to 7 days after surgery, rate of wound epithelialization, and scar parameters at 3 and 12 months postoperatively. Graft take and wound epithelialization did not differ significantly between groups. Most measures of scar quality also did not differ significantly between groups.
Traumatic and Surgical Wounds
A 2012 Cochrane review evaluated the evidence on NPWT for skin grafts and surgical wounds expected to heal by primary intention.(16)
Healing by primary intention occurs when the wound edges are brought together with sutures, staples, tape, or glue, and contrasts with healing by secondary intention, where the wound is left open to heal from the bottom up (eg, for chronic or infected wounds). Five randomized trials with a total of 280 subjects were included in the review. Four trials compared NPWT with another type of wound dressing, and 1 trial compared different NPWT devices. Outcomes were measured between 4 days and 12 months after surgery. All trials were considered to have unclear or high risk of bias, and few trials reported the primary outcome measure of interest for the review (proportion of wounds completely healed). Based on analysis of subsets of the studies, there were no significant differences in the proportion of wounds completely healed, time to healing, incidence of seromas, or failed skin grafts. The review concluded that evidence on the effectiveness of NPWT on complete healing of wounds expected to heal by primary intention remains unclear, and that there is a need for high-quality trials with newer NPWT devices.
Identified studies describe a variety of wound types treated over periods ranging from several days to several months.
The largest trial on surgical wounds is a 2011 report from an investigator-initiated, industry-sponsored multicenter RCT of inpatient NPWT for closed surgical incisions.(17) (A preliminary report was published in 2006.18 ) Included were 249 blunt trauma patients with 263 high-risk fractures (tibial plateau, pilon, calcaneus) requiring surgical stabilization. Patients were randomized to NPWT applied to the closed surgical incision or to standard postoperative dressings. All patients were maintained as inpatients until wound drainage was minimal, at which time NPWT was discontinued (mean, 59 hours; range, 21-213). Patients in the NPWT group were ready for discharge in 2.5 days compared with 3.0 days for the control group; this was not significantly different. The NPWT-treated group had significantly fewer infections than the control group (10% vs 19% of fractures, p=0.049). Wound dehiscence after discharge was observed less frequently in the NPWT group than in the control group (8.6% vs 16.5%). These results may reflect the efficacy of short-term use of NPWT under highly controlled conditions of inpatient care, but do not address the effectiveness of NPWT in the outpatient setting.
In 2005, Armstrong et al reported an RCT of NPWT using the V.A.C.® system (n=77) and standard moist wound care (n=85) to treat partial foot amputation wounds (average wound duration: 1.5 months) in diabetic patients.(19) Forty-three (56%) of NPWT patients achieved complete closure during the 16-week assessment period versus 33 (39%) of controls (p=0.040). Log-rank analysis showed the rate of complete closure was significantly faster with NPWT compared with controls. Frequency and severity of adverse events, most commonly infection (32% in both groups), were similar. Intention-to-treat analysis was reported, but substantial unaccounted loss to follow-up (23%), lack of allocation concealment in randomization, and between-group differences in wound care limits interpretation of these results.
Other randomized studies have reported no benefit of NPWT. Masden et al (2012) reported a randomized trial of NPWT for surgical closures at high risk for nonhealing in 81 patients with comorbidities that included diabetes and peripheral vascular disease.(20) At a mean of 113 days follow-up, there was no significant difference in the proportion of patients with wound infection, time to develop infection, or dehiscence between NPWT and dry dressing groups. Chio and Agrawal (2010) published results of a randomized trial of 54 patients comparing NPWT with a static pressure dressing for healing of the radial forearm free flap donor site.(21) There were no statistically significant differences in wound complications or graft failure (percentage of area for graft failure was 7.2% for negative pressure and 4.5% for standard dressing). Biter et al (2014) found no significant advantage of 2 weeks of NPWT in a study of 49 patients who underwent surgical excision for pilonidal sinus disease.(22) Complete wound healing was achieved at a median of 84 days in the NPWT group and 93 days in controls.
A 2007 Cochrane review of the literature on NPWT for treatment of partial thickness burns found only 1 RCT that satisfied inclusion criteria, and methodologic quality of the trial was poor.(23) The authors concluded that there is a “paucity of high quality [randomized, controlled trials] on NPWT for partial thickness burn injury with insufficient sample size and adequate power to detect differences, if there are any, between NPWT and conventional burn wound therapy dressings.”
In 2011, Petkar et al published an RCT comparing 4 days of NPWT with a locally constructed device versus conventional dressing methods for split-thickness skin grafts.(24) Forty grafts in 30 burn patients were included in the study. The percentage of graft take at 9 days after surgery was assessed by consensus of the treating plastic surgery unit after gross examination and was significantly greater in the NPWT-treated grafts (96.7% vs 87.5%). Mean duration of continued dressing on the grafted area was 8 days for NPWT and 11 days in controls. Duration of therapy was a clinical decision made by the surgeon, taking into account adherence and stability of the graft.
An expert panel convened to develop evidence-based recommendations for the use of NPWT reported that the evidence base in 2011 was strongest for the use of NPWT on skin grafts and weakest as a primary treatment for burns.(25)
Nonpowered NPWT Devices
One ultraportable, nonpowered (mechanical) gauze-based NPWT device (SNaP Wound Care System) designed to remove small amounts of exudate from chronic, traumatic, dehisced, acute, subacute wounds and diabetic and pressure ulcers became available in 2009.
In 2011, Armstrong et al reported results of a planned interim analysis of an RCT comparing SNaP and the KCI Wound VAC Therapy System for the treatment of chronic lower-extremity wounds.(26) Final results of this industry-sponsored multicenter noninferiority trial were reported in 2012.27 The study randomized 132 patients with lower-extremity venous or diabetic ulcers with surface area between 1 and 100 cm2 and diameter less than 10 cm and present more than 30 days, despite appropriate care. Dressings were changed per manufacturer direction, 2 times per week in the SNaP group and 3 times per week in the VAC group. Patients were assessed for up to 16 weeks or until complete wound closure; 83 patients (63%) completed the study. Intention-to-treat analysis with the last observation carried forward showed noninferiority in the primary outcome of wound size reduction at 4, 8, 12, and 16 weeks. When adjusted for differences in wound size at baseline, SNaP-treated subjects showed noninferiority to VAC-treated subjects at 4, 12, and 16 weeks. Kaplan-Meier analysis showed no significant difference in complete wound closure between the 2 groups. At the final follow-up, 65.6% of the VAC group and 63.6% of the SNaP group had wound closure. Survey data indicated that dressing changes required less time, and use of the SNaP device interfered less with mobility and activity than the VAC device. This study is limited by high loss to follow-up and lack of comparison with standard treatment protocols.
A retrospective study with historical controls compared NPWT using the SNaP device (n=28) with wound care protocols that included the use of Apligraf, Regranex, and skin grafting (n=42) for treatment of lower-extremity ulcers.(28) Seven patients (25%) in the SNaP-treated group could not tolerate the treatment and were discontinued from the study because of complications (allergic skin reaction [n=1], wound infection
[n=1], bleeding after débridement preventing reapplication [n=1], worsening lower-extremity edema [n=1], and development of maceration severe enough to require discontinuation [n=3]) and were considered treatment failures. Between-group estimates of time-to-wound healing by Kaplan-Meier analysis favored the SNaP treatment group. This study is limited by the use of historical controls, the multiple modalities used to treat controls, and the large number of dropouts. The authors noted that patients in the SNaPtreated group may have benefited from being in an experimental environment, particularly because wounds in this group were seen twice per week compared with variable follow-up in historical controls.
Clinical Input Received From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.
In response to requests, input was received from 2 physician specialty societies and 3 academic medical centers while this policy was under review in 2010. The input was near uniform in support of a therapeutic trial of NPWT for chronic pressure ulcers that have failed to heal, for traumatic or surgical wounds that have failed to close when there is exposed bone, cartilage, tendon, or foreign material within the wound, and for nonhealing wounds in patients with underlying clinical conditions known to negatively impact wound healing. Most of the input agreed that therapeutic trials of NPWT for other acute or chronic wounds would be not medically necessary.
Summary of Evidence
Negative pressure wound therapy (NPWT) consists of the use of a negative pressure therapy or suction device to aspirate and remove fluids, debris, and infectious materials from the wound bed to promote the formation of granulation tissue. Evidence from comparative clinical trials demonstrated that there is a subset of problematic wounds for which the use of NPWT may provide a significant clinical benefit.
However, due to clinical variability and limited data, it is not possible to determine prospectively which wounds are most likely to respond favorably to NPWT. Therefore, the policy statement indicates that a therapeutic trial of NPWT of not less than 14 days may be considered medically necessary for chronic wounds that have failed to heal, despite intense conventional wound therapy for at least 90 days, or for those acute and chronic wounds that have a high probability of failure to heal due to compounding factors involving the wound and the patient. Continued use of NPWT requires objective evidence of wound healing such as the development of healthy granulation tissue and progressive wound contracture.
Use of NPWT for other wounds is considered not medically necessary because these wounds are likely to heal with conventional wound management, ie, the evidence does not demonstrate an incremental improvement in wound healing with use of NPWT for these cases.
Reports with small numbers of patients using the nonpowered (mechanical) gauze-based NPWT system are insufficient to draw conclusions about its impact on net health outcome, both for the device itself and in comparison with current care. There are important unanswered questions about efficacy and tolerability. Well-designed comparative studies with larger numbers of patients are needed. Because the
impact on net health outcome compared with existing technology is unknown, this is considered investigational.
Practice Guidelines and Position Statements
In 2011, an international expert panel on NPWT provided evidence-based recommendations for the use of NPWT in chronic wounds.(29) The expert panel gave a grade C recommendation (based on wellconducted case-control or cohort studies) that NPWT may be used for grade 3 and 4 pressure ulcers until surgical closure is possible/desirable and a grade B recommendation (based on high-quality systematic reviews of case-control or cohort studies) to achieve closure by secondary intention, to reduce wound dimensions, and to improve the quality of the wound bed. For diabetic foot ulcers, the expert panel gave a grade A recommendation (high-quality meta-analyses, systematic reviews of randomized controlled trials [RCTs], or RCTs with very low risk of bias) that NPWT must be considered as an advanced wound care therapy and must be considered to achieve healing by secondary intention, and a grade B recommendation that NPWT should be considered in an attempt to prevent amputation or reamputation. Use of NPWT in ischemic lower-limb wounds received a grade C recommendation that NPWT may be considered in specialist hands but never as an alternative for revascularization and a grade D recommendation (based on case series or expert opinion) that the use of NPWT is not indicated in acute limb ischemia. Use of NPWT in venous leg ulcers received a grade B recommendation that as first-line therapy, (compression) is not efficacious; NPWT should be considered to prepare the wound for surgical closure.
Guidelines for the prevention of infections associated with combat-related injuries were endorsed in 2011 by the Infectious Diseases Society of America (IDSA) and the Surgical Infection Society.(30) The guidelines provide a IB recommendation (strong recommendation, moderate-quality evidence) that NPWT should be used in the management of open wounds (excluding central nervous system injuries) to include during
aeromedical evacuation of patients.
2012 guidelines from IDSA for the diagnosis and treatment of diabetic foot infections state that no adjunctive therapy has been proven to improve resolution of infection, but for selected diabetic foot wounds that are slow to heal, clinicians might consider using negative wound therapy (weak recommendation, low quality evidence).(31)
The United Kingdom’s National Institute for Health and Clinical Excellence (NICE) stated in 2009 that current evidence on the safety and efficacy of NPWT for the open abdomen is inadequate in quality and quantity, and clinicians should make special arrangements for audit of the management of all patients with an open abdominal wound.(32)
The 2005 guidance on the management of pressure ulcers in primary and secondary care from the Royal College of Nursing and NICE stated that topical negative pressure treatment was only assessed in one trial with a small sample size and methodologic limitations; while trial results suggested that topical negative pressure treatment may increase healing rates of pressure ulcers compared with saline gauze dressings, these findings must be viewed with extreme caution. “Practitioners ought to make patients aware of the limited trial-based evidence for the effectiveness of topical negative pressure for pressure ulcer healing and that further research is required to validate the preliminary findings.”(33)
The 2007 guidelines from the American Society of Plastic Surgeons states that maintaining a moist environment, while simultaneously removing soluble factors detrimental to wound healing might logically provide optimal conditions for wound healing.(34) Classic dressings include gauze, foam, hydrocolloid, and hydrogels. Fluid-handling mechanisms include absorption, gelling, retention, and vapor transmission.
Bioactive dressings include topical antimicrobials, bioengineered composite skin equivalent, bilaminar dermal regeneration template, and recombinant human growth factor. Finally, NPWT is a mechanical treatment that uses negative pressure to remove wound exudate. Although the wound care literature is rife with uncontrolled studies reporting the effectiveness of NPWT, few prospective randomized trials exist. Despite a lack of strong evidence to support its use, NPWT has gained wide acceptance by multiple specialties for a myriad of wounds.
Included in the American College of Foot and Ankle Surgeons 2006 guideline on diabetic foot disorders is the following information on NPWT35 : NPWT has become a common adjunctive treatment modality for diabetic foot ulcerations. Use of a vacuum-assisted closure® device (V.A.C.®; KCI, San Antonio, TX) promotes wound healing through the application of topical, subatmospheric, or “negative” pressure to the
wound base. This therapy removes edema and chronic exudate, reduces bacterial colonization, enhances formation of new blood vessels, increases cellular proliferation, and improves wound oxygenation as the result of applied mechanical force. These actions are synergistic. Numerous applications of this modality have proven successful, including use over exposed bone, tendons, and hardware to generate granulation tissue. It is also frequently used to facilitate adherence of split-thickness skin grafts, rotational flaps, or tissue substitutes to a wound bed. A recent clinical trial of the V.A.C.® device for the treatment of open amputation wounds in the diabetic foot showed significantly faster healing and development of granulation tissue with NPWT compared with standard moist wound care.
U.S. Preventive Services Task Force Recommendations
Medicare National Coverage
In October 2000, Healthcare Financing Administration (now Centers for Medicare and Medicaid Services) issued the following durable medical equipment regional carrier coverage policy, which stated that patients meeting the following criteria would be eligible for negative wound pressure therapy in the home setting:
Patient has a chronic Stage III or Stage IV pressure ulcer, venous or arterial insufficiency ulcer, or a chronic ulcer of mixed etiology. A complete wound therapy program should have been tried or considered and ruled out prior to application of NPWT.
- Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Vacuum-assisted closure in the treatment of chronic wounds. TEC Assessments. 2000;Volume 15, Tab 23. PMID
- Samson D, Lefevre F, Aronson N. Wound-healing technologies: low-level laser and vacuumassisted closure. Evidence Report/Technology Assessment No. 111. (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center, under Contract No. 290-02-0026.) AHRQ Publication No. 05-E005-2. Rockville, MD: Agency for Healthcare Research and Quality. Dec 2004. PMID 15663354
- Ubbink DT, Westerbos SJ, Evans D, et al. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev. 2008(3):CD001898. PMID 18646080
- Rhee SM, Valle MF, Wilson LM, et al. Negative Pressure Wound Therapy Technologies For Chronic Wound Care in the Home Setting. Evidence Report/Technology Assessment. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-201-200007-I.) Rockville, MD: Agency for Healthcare Research and Quality. September 15, 2014. http://www.cms.gov/Medicare/Coverage/DeterminationProcess/Downloads/id96ta.pdf. Accessed December 16, 2014.
- Sullivan N, Snyder DL, Tipton K, et al. Technology assessment: Negative pressure wound therapy devices. 2009; www.ahrq.gov/clinic/ta/negpresswtd. Accessed November, 2014.
- Peinemann F, Sauerland S. Negative-pressure wound therapy: systematic review of randomized controlled trials. Dtsch Arztebl Int. Jun 2011;108(22):381-389. PMID 21712971
- Moues CM, Vos MC, van den Bemd GJ, et al. Bacterial load in relation to vacuum-assisted closure wound therapy: a prospective randomized trial. Wound Repair Regen. Jan-Feb2004;12(1):11-17. PMID 14974959
- Braakenburg A, Obdeijn MC, Feitz R, et al. The clinical efficacy and cost effectiveness of the vacuum-assisted closure technique in the management of acute and chronic wounds: a randomized controlled trial. Plast Reconstr Surg. Aug 2006;118(2):390-397; discussion 398-400. PMID 16874208
- Mody GN, Nirmal IA, Duraisamy S, et al. A blinded, prospective, randomized controlled trial of topical negative pressure wound closure in India. Ostomy Wound Manage. Dec 2008;54(12):36-46. PMID 19104122
- Wanner MB, Schwarzl F, Strub B, et al. Vacuum-assisted wound closure for cheaper and more comfortable healing of pressure sores: a prospective study. Scand J Plast Reconstr Surg Hand Surg. 2003;37(1):28-33. PMID 12625392
- Dumville JC, Hinchliffe RJ, Cullum N, et al. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. Cochrane Database Syst Rev. 2013;10:CD010318. PMID 24132761
- Blume PA, Walters J, Payne W, et al. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care. Apr 2008;31(4):631-636. PMID 18162494
- Vuerstaek JD, Vainas T, Wuite J, et al. State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings. J Vasc Surg. Nov 2006;44(5):1029-1037; discussion 1038. PMID 17000077
- Dumville JC, Munson C. Negative pressure wound therapy for partial-thickness burns. Cochrane Database Syst Rev. 2012;12:CD006215. PMID 23235626
- Bloemen MC, van der Wal MB, Verhaegen PD, et al. Clinical effectiveness of dermal substitution in burns by topical negative pressure: a multicenter randomized controlled trial. Wound Repair Regen. Nov-Dec 2012;20(6):797-805. PMID 23110478
- Webster J, Scuffham P, Sherriff KL, et al. Negative pressure wound therapy for skin grafts and surgical wounds healing by primary intention. Cochrane Database Syst Rev. 2012;4:CD009261. PMID 22513974
- Stannard JP, Volgas DA, McGwin G, 3rd, et al. Incisional negative pressure wound therapy after high-risk lower extremity fractures. J Orthop Trauma. Jan 2012;26(1):37-42. PMID 21804414
- Stannard JP, Robinson JT, Anderson ER, et al. Negative pressure wound therapy to treat hematomas and surgical incisions following high-energy trauma. J Trauma. Jun 2006;60(6):1301-1306. PMID 16766975
- Armstrong DG, Lavery LA. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. Nov 12 2005;366(9498):1704-1710. PMID 16291063
- Masden D, Goldstein J, Endara M, et al. Negative pressure wound therapy for at-risk surgical closures in patients with multiple comorbidities: a prospective randomized controlled study. Ann Surg. Jun 2012;255(6):1043-1047. PMID 22549748
- Chio EG, Agrawal A. A randomized, prospective, controlled study of forearm donor site healing when using a vacuum dressing. Otolaryngol Head Neck Surg. Feb 2010;142(2):174-178. PMID 20115970
- Biter LU, Beck GM, Mannaerts GH, et al. The use of negative-pressure wound therapy in pilonidal sinus disease: a randomized controlled trial comparing negative-pressure wound therapy versus standard open wound care after surgical excision. Dis Colon Rectum. Dec 2014;57(12):1406-1411. PMID 25380007
- Wasiak J, Cleland H. Topical negative pressure (TNP) for partial thickness burns. Cochrane
- Petkar KS, Dhanraj P, Kingsly PM, et al. A prospective randomized controlled trial comparing negative pressure dressing and conventional dressing methods on split-thickness skin grafts in burned patients. Burns. Sep 2011;37(6):925-929. PMID 21723044
- Runkel N, Krug E, Berg L, et al. Evidence-based recommendations for the use of Negative Pressure Wound Therapy in traumatic wounds and reconstructive surgery: steps towards an international consensus. Injury. Feb 2011;42 Suppl 1:S1-12. PMID 21316515
- Armstrong DG, Marston WA, Reyzelman AM, et al. Comparison of negative pressure wound therapy with an ultraportable mechanically powered device vs. traditional electrically powered device for the treatment of chronic lower extremity ulcers: a multicenter randomized-controlled trial. Wound Repair Regen. Mar-Apr 2011;19(2):173-180. PMID 21362084
- Armstrong DG, Marston WA, Reyzelman AM, et al. Comparative effectiveness of mechanically and electrically powered negative pressure wound therapy devices: a multicenter randomized controlled trial. Wound Repair Regen. May-Jun 2012;20(3):332-341. PMID 22564228
- Lerman B, Oldenbrook L, Eichstadt SL, et al. Evaluation of chronic wound treatment with the SNaP wound care system versus modern dressing protocols. Plast Reconstr Surg. Oct 2010;126(4):1253-1261. PMID 20885246
- Vig S, Dowsett C, Berg L, et al. Evidence-based recommendations for the use of negative pressure wound therapy in chronic wounds: steps towards an international consensus. J Tissue Viability. Dec 2011;20 Suppl 1:S1-18. PMID 22119531
- Hospenthal DR, Murray CK, Andersen RC, et al. Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. J Trauma. Aug 2011;71(2 Suppl 2):S210-234. PMID 21814089
- Lipsky BA, Berendt AR, Cornia PB, et al. Infectious Diseases Society of America (IDSA), Clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clinical Infectious Diseases 2012;54(12):132–173. http://cid.oxfordjournals.org/content/54/12/e132.full.pdf+html.Accessed November, 2014.
- National Institute for Health and Clinical Excellence (NICE). Negative Pressure Wound Therapy for the Open Abdomen. IPG 322. 2009;
http://www.nice.org.uk/nicemedia/pdf/IPG322Guidance.pdf. Accessed November, 2014.
- Royal College of Nursing and National Institute for Health and Clinical Excellence. The Management of Pressure Ulcers in Primary and Secondary Care. Clinical Guidance 29. 2005; http://guidance.nice.org.uk/CG29/Guidance/pdf/English. Accessed November, 2014.
- American Society of Plastic Surgeons (ASPS). Evidence-based Clinical Practice Guideline: Chronic Wounds of the Lower Extremity. 2007; http://www.plasticsurgery.org/Documents/medicalprofessionals/health-policy/evidence-practice/Evidence-based-Clinical-Practice-Guideline-Chronic-Wounds-of-the-Lower-Extremity.pdf. Accessed November, 2014.
- American College of Foot and Ankle Surgeons (ACFAS). Diabetic Foot Disorders: A Clinical Practice Guideline. 2006; http://www.acfas.org/Research-and-Publications/Clinical-Consensus-Documents/Clinical-Consensus-Documents/. Accessed November, 2014. Database Syst Rev. 2007(3):CD006215. PMID 17636835
|CPT||97605||Negative pressure wound therapy (e.g., vacuum-assisted drainage collection), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters|
|97606||total wound(s) surface area greater than 50 square centimeters|
|97607||Negative pressure wound therapy (eg, vacuum assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management collection system, topical application(s), wound assessment, and instructions for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters (new code 01/01/15)|
|97608||total wound(s) surface area greater than 50 square centimeters(new code 01/01/15)|
|ICD-9 Procedure||No Code|
|ICD-9 Diagnosis||707.00-707.09||Pressure ulcer code range|
|873.1-897.7||Open wound code range. Codes with “complicated” in the code description include delayed healing. Possible codes include:
875.1 – chest wall, complicated
877.1 – buttock, complicated
879.3 – abdominal wall, anterior, complicated
879.5 – abdominal wall, lateral, complicated
890.1 – hip or thigh, complicated
892.1 – foot (including heel) complicated
|998.83||Non-healing surgical wound|
|HCPCS||A6650||Wound care set, for negative pressure wound therapy electrical pump, includes all supplies and accessories|
|A7000-A7001||Canister for use with suction pump, code range|
|A9272||Mechanical wound suction, disposable, includes dressing and all accessories and components, each|
|E2402||Negative pressure wound therapy electrical pump, stationary or portable|
|K0743||Suction pump, home model, portable, for use on wounds|
|G0456-G0457||Negative pressure wound therapy (e.g., vacuum assisted drainage collection) using a mechanically-powered device, not durable medical equipment, including provision of cartridge and dressing(s), topical application(s), wound assessment, and instructions for ongoing care, per session code range|
|K0744-K0746||Code range for absorptive wound dressings to be used with home suction pump coded with K0743|
|ICD-10-CM (effective 10/1/15)||L89.000-L89.899||Pressure ulcer code range, specified site, code range includes options for all body areas as well as designation of stages|
|L89.90-L89.95||Pressure ulcer code range, unspecified site, code range includes options for stage of ulcer|
|S01.00xA – S01.95xS||Open wound of head and face, code range, 7th digit extender includes stage of healing|
|S11.80xA – S11.95xS||Open wound of neck, code range, 7th digit extender includes stage of healing|
|S31.00xA – S31.839S||Open wound of abdomen, lower back, pelvis and external genitals, code range, 7th digit extender includes stage of healing|
|S41.001A – S41.159S||Open wound of shoulder and upper arm, code range, 7th digit extender includes stage of healing|
|S51.001A – S51.859S||Open wound of elbow and forearm, code range, 7th digit extender includes stage of healing|
|S61.001A – S61.559S||Open wound of wrist, hand and fingers, code range, 7th digit extender includes stage of healing|
|S71.001A – S71.159S||Open wound of hip and thigh, code range, 7th digit extender includes stage of healing|
|S81.001A – S81.859S||Open wound of knee and lower leg, code range, 7th digit extender includes stage of healing|
|S91.001A – S91.359S||Open wound of ankle, foot and toes, code range, 7th digit extender includes stage of healing|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for this therapy.|
|6A0Z0ZZ||Atmospheric control, single duration|
|6A0Z1ZZ||Atmospheric control, multiple durations|
|Type of Service:||Durable medical equipment|
|Place of Service:||Home
Skilled nursing facility
Negative Wound Pressure Therapy
Negative Pressure Vacuum-Assisted Closure of Wounds
Vacuum-Assisted Wound Closure
Wounds, Negative Pressure Vacuum-Assisted Closure
|01/30/98||Add to Durable Medicine section||New policy|
|05/31/01||Replace policy||Policy revised with reference to TEC Assessment; policy statement unchanged|
|07/12/02||Replace policy||Policy reviewed; policy statement unchanged|
|10/9/03||Replace policy||Policy reviewed with literature search; policy statement unchanged; new 2004 HCPCS codes added|
|11/9/04||Replace policy||Policy reviewed with literature search; policy statement unchanged|
|2/01/07||Replace policy||Local policy revision|
|4/14/11||Replace policy||Policy updated with literature search, reference numbers 31-42 added, term “powered” added to existing policy statements which are unchanged, new policy statement added that non-powered NPWT systems are investigational|
|1/12/12||Replace policy||Policy updated with literature search through November 2011; Rationale section revised; 10 references added and references reordered. Clinical input that had been received in 2010 and clinical guidelines added to policy; policy statement for continuation of powered NPWT clarified|
|1/10/13||Replace policy||Policy updated with literature search through November 2012; references 24, 41 and 46 added; policy statements unchanged.|
|4/11/13||Replace policy-coding update only||Added HCPCS codes G0456 and G0457|
|1/09/14||Replace policy||Policy updated with literature review through December 5, 2013; references 16, 19, 20 added; policy statements unchanged|
|1/15/15||Replace policy||Policy updated with literature review through December 11, 2014; references 4, 22, 31 added and some references removed; policy statements unchanged|